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Background: To explore the relationship between the liver X receptor α gene (LXRα) rsl2221497 polymorphism
and the susceptibility of coronary heart disease (CHD) and serum lipids and glucose levels.
Methods: The single fluorescently labeled probes technique was used to detect the genotype of rsl2221497 in
LXRα gene in 240 CHD patients and 250 healthy control subjects. The difference of genotype distribution between
the two groups was analyzed using of Chi-square test. The serum lipids and glucose levels between the different
genotypes were also compared.
Results: The risk of CHD in carriers with (AA + GA) genotype was 1.76 times as that in the GG genotype carriers
(OR = 1.76, 95% CI: 1.18-2.87, P <0.05), and the risk of CHD in carriers with A allele increased 0.88 times compared to
that in G allele carriers (OR = 1.88, 95% CI:1.21-3.43, P <0.01). Logistic regression analysis showed that after adjusting
for other confounding factors, A allele was an independent risk for CHD. However, there were no differences in
serum lipids and glucose levels between each genotype.
Conclusions: The rsl2221497 polymorphism in LXRα gene was associated with susceptibility of CHD in Han population.
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Coronary heart disease (CHD) is a multifactorial disease
resulting from the interaction between genetic factors
and environmental factors [1-4]. Currently, it is consid-
ered that vascular endothelial cell injury, platelet re-
activity, lipid infiltration, vascular smooth muscle cell
proliferation and increased synthesis of connective tissue
are the main pathological processes of CHD [5,6]. Lipid
metabolism disorder, especially elevated serum LDL-C is
an independent risk factor for CHD [7]. Liver X receptor
α (LXRα) is a class of nuclear receptor family members
[8]. These members are mainly distributed in the liver,
adipose tissue, kidney, small intestine and macrophages,
and the main physiological function is to control stable
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physiological role of LXR α in humans is not entirely
understood, but some researchers identified this gene as
a candidate gene of metabolic syndrome and diabetes
[11,12]. Diabetes is equivalent risk of CHD, however,
there was still no research data on the relation between
gene polymorphism of LXRα and CHD. In the present
study, we performed a case - control study to analyze
the association of LXRα gene polymorphism with CHD
in a Chinese Han population.Methods
Ethnics
The present study has been performed with the approval
of the ethics committee of General Hospital of the Air
Force PLA and is in compliance with the Helsinki Dec-
laration. The informed consents of the study were col-
lected from all the candidate subjects.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and risk profile of the
study population
Risk factors No. (%) or Mean ± SD P values
Control (n = 250) CHD (n = 240)
Age (years) 61.43 ± 11.21 61.22 ± 10.22 0.332
Female (%) 58 (24.2) 49 (19.6) 0.130
BMI (Kg/m2) 24.52 ± 3.40 24.76 ± 3.91 0.101
GLU (mmol/L) 4.20 ± 0.55 5.27 ± 0.75 <0.001
TG (mmol/L) 1.36 ± 0.64 2.13 ± 0.44 <0.001
TC (mmol/L) 4.29 ± 0.79 5.12 ± 0.87 0.005
HDL-C (mmol/L) 1.29 ± 0.49 1.01 ±0.44 0.043
LDL-C (mmol/L) 2.26 ± 0.80 2.89 ±0.81 0.038
Smoking (n) 97 132 0.011
Hypertension (n) 82 144 0.002
Diabetes (n) 44 87 0.016
Obesity (n) 68 79 0.077
Note: HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG: Triglycerides;
TC: Cholesterol; BMI: Body mass index; GLU: Glucose.
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From August, 2009 to June, 2012, two hundred and forty
hospitalized patients diagnosed as CHD in our hospital
were enrolled as the case group, in which one hundred
and ninety-one patients were male and forty-nine patients
were female. The average age was 61.22 ± 10.22 years.
CHD was diagnosed according to WHO issued ischemic
heart disease diagnostic criteria in 1979. In the light of
coronary angiography, ≥ 50% of stenosis of the main
branches was defined as CHD.
In control group, 250 healthy inpatients were selected
during the same period in our hospital, 192 were male and
58 were female with mean age of 61.43 ± 11.21 years. The
disease history, physical examination, laboratory tests
(serum, urine, stool routine tests, serum lipids and glu-
cose), ECG and other preliminary tests were performed.
The history of CHD, hypertension and diabetes were de-
tected. All the subjects were Han Chinese people.
Clinical data collection
The clinical data including past medical history, family
disease history, smoking and drinking history, weight,
height, blood pressure, body mass index (BMI) were col-
lected in the present study.
2 mL of 12 h-fasting venous blood was collected, and
the triglyceride (TG), total cholesterol (TC), high density
lipoprotein cholesterol (HDL-C), low density lipoprotein
cholesterol (LDL-C), fasting blood glucose (FBG) and
other biochemical parameters were detected using bio-
chemical analyzer (NJ, USA).
Preparation of DNA from peripheral blood leukocytes
100 uL of EDTA anti-coagulated blood was taken, and
the blood genomic DNA was extracted from whole
blood according to the protocol of DNA-extraction kit
(Shanghai Shennengbocai company) and was dissolved
in TE solution and stored at -20°C refrigerator.
Instrument and reagents
Light Cycler gene amplification detector was utilized for
PCR reaction. Taq DNA polymerase, 4 × dNTPs, 10 ×
Bufier buffer and MgCl2 were purchased from Shanghai
Shennengbocai company (Shanghai, China). Primer se-
quence was as follows: upstream primer: 5 '-GGCTTACTC
CAA TAA TCC CCA CAC TT-3’, downstream primer: 5'-
AAGGAAGAAGGCAGGTAATGATGAAGGAG-3' (syn-
thesized and modified by Shanghai Sangon Biotechnology
Co., Ltd.).
Statistical analysis
Statistical analysis was performed using SPSSl3.0 (IL,
USA). Continuous data were expressed as mean ± stand-
ard deviation (M ± SD). Difference between the two
groups was compared by using of t test. Genotype andallele frequency distribution in the case group and the
control group were calculated with direct counting
method. Hardy-Weinberg equilibrium was performed
using Chi-square test, genotype and allele frequencies
distribution between the two groups were compared
using chi-square test or Fisher's exact test. Multivariate
Logistic regression model was used to analyze risk fac-
tors of CHD, the odds ratios (OR) and 95% confidence
intervals (95% CI) were used to express the relative risk.
Results
Genotyping results
Three genotypes were detected in rsl2221497, namely as
GG homozygote, AA homozygote, GA heterozygote.
General clinical data comparison in the control group and
the CHD group
The mean age, sex and body mass index (BMI) were not sig-
nificantly different between the two groups (P > 0.05). How-
ever, there were significant difference between the two group
in TG, TC, HDL-C, LDL-C, FBG (all P <0.05, Table 1).
Genotype and allele frequency distribution
Genotypes in CHD and the control group were in line
with Hardy-Weinberg equilibrium (P > 0.05) indicating
that the genotype frequency distribution reached the
genetic equilibrium, the sample can represent the whole
group. Genotype analysis showed that the CHD risk in
AA +GA genotype carriers was1.76 times as that in GG
genotype carriers (OR = 1.76, 95% CI: 1.18-2.87, P <0.05).
A allele frequency in CHD group was significantly higher
than that in control group (P <0.01), and the odds ratio
(OR) was 1.88 (95% CI:1.21-3.43), Table 2.
Table 2 Distributions of SNPs of LXR gene in case and
control group
rsl2221497 Genotypes Group P value
Control, n (%) CHD, n (%)
Genotype GG 215 (86.0) 185 (77.1) 0.012
GA 33 (13.2) 48 (20.0)
AA 2 (0.8) 7 (2.9)
Allele G 463 (92.6) 425 (87.1) 0.004
A 37 (7.4) 55 (12.9)
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There were a total of 490 cases in coronary heart disease
and the control group, 400 cases had GG genotype and
90 cases had GA + AA genotype. The difference of TG,
TC, HDL-C, LD-C, FBG between the different genotypes
was not shown statistically significant (P > 0.05), Table 3.
Logistic regression analysis
In multivariate Logistic regression analysis, the CHD
was taken as the dependent variable. The age, sex, BMI,
TC, TG, LDL-C, HDL-C, FBG, A allele, smoking history,
hypertension history, diabetes mellitus history were
taken as independent variables in Logistic regression
analysis. The results showed that HDL-C, TC, TG, his-
tory of hypertension, smoking history, age, BMI, A allele
were independent risk factors for CHD, the OR for A al-
lele was 1.85 (P <0.05, 95% CI: 1.09 ~ 3.55) after adjust-
ment of other confounders.
Discussion
In this study, we found that in Han population, LXRα A
allele increased the risk of CHD. This result was consist-
ent with LXRα physiological role in the human body.
LXRα can regulate many target genes involved in lipid
uptake, spillover and lipid metabolism [13]. The regula-
tion function of activated LXR α was as follows: 1) it can
mediate the binding and transporting factor Al (ABCAl),
ABCGl, ABCG5, ABCG4, ABCG8 located in the human
macrophages and small intestine target genes ATP to




No. (%) or Mean ± SD P values
GG (n = 400) GA + AA (n = 90)
GLU (mmol/L) 4.88 ± 0.76 4.97 ± 0.64 0.432
TG (mmol/L) 1.75 ± 0.68 1.78 ± 0.49 0.654
TC (mmol/L) 4.58 ± 0.87 4.69 ± 0.66 0.179
HDL-C (mmol/L) 1.14 ± 0.33 1.10 ±0.43 0.186
LDL-C (mmol/L) 2.47 ± 0.88 2.64 ±0.75 0.078
Note: HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG: Triglycer-
ides; TC: Cholesterol; BMI: Body mass index; GLU: Glucose.can activate human macrophages Niemann - Pick Cl
protein (NPCI) and C2 protein (NPC2) to promote chol-
esterol transport from endosomes chamber to the cyto-
plasmic membrane; 3) it can promote receptor ApoE,
ApoC-I, C-II, C-IV expression which were in charge of
regulating the cholesterol outflow in adipocytes and mac-
rophages; 4) it can control the liver and macrophages
regulating enzymes such as phospholipid transfer protein
(PLTP), lipoprotein lipase (LPL) remodeling lipoproteins.
Meanwhile LXR α can inhibit many inflammatory cyto-
kines and the expression of chemokines [14-18]. All these
indicated that LXR α signaling pathway played an import-
ant role in the development of atherosclerosis. The mice
tests also proved this view, the synthesis of liver X recep-
tor agonist can inhibit the development of atherosclerosis,
and the effects may be due to regulation of the underlying
metabolic and inflammatory gene expression [19,20].
Our studies suggested that in Chinese Han patients with
CHD, the LXRα A allele frequency was significantly higher
than that in the healthy population, A allele carries had
0.8 times increased risk of CHD (OR = 1.81). In the multi-
variate Logistic regression analysis, after the adjustment of
age, sex, cholesterol, fasting glucose, hypertension, dia-
betes, smoking history and other confounding factors, A
allele was still a risk factor of CHD independent of other
traditional risk factors (P <0.05) which indicated that this
locus had significantly increased risk for CHD. A recent
study indicated that in the female population, LXR α poly-
morphism was significantly correlated with BMI and
HDL-C concentration [21]. In a French-Canadians popu-
lation, the serum cholesterol levels in A allele carriers were
higher than those in GG homozygotes carriers [22]. The
dietary cholesterol intake and this locus polymorphism
had the combined effects on plasma TC and LDL-C levels
suggesting that the plasma lipoprotein concentrations
were not only associated with dietary cholesterol, but also
regulated by LXR α gene expression. This locus was in
recognition area of LXRα gene transcription factor and
was involved in LXRα transcriptional regulation. In the
present study, we did not find significant differences in
lipids and BMI between A allele carriers and GG homozy-
gotes carriers. This suggested that there may exist hetero-
geneity between different ethnics and populations, the diet
and racial and body size differences between Han popula-
tion and Caucasian may also be an explanation.
There were several limitations in our study. Firstly, the
relative small sample size may reduce the statistics
power and overestimate the OR value. Secondly, in the
present study, we only investigated one SNP in LXRα
gene. Although many previous studies suggested this
SNP was associated risk factors of CHD, this SNP may
not figure out the relationship between LXRα poly-
morphism and serum lipids and CHD risk. Finally, we
only investigate this association in one case-control
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cation was not designed.
Conclusion
In conclusion, this study first reported the association
between genetic variation of LXR α gene and CHD in
Han population. It provided some new clues to further
understand the mechanism of the development of CHD
and prevention. The study also confirmed from the gen-
etic level that the lipid metabolism was the risk factor
of CHD.
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